Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bevacizumab | Avastin | VEGF Antibody 17 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Pegylated liposomal doxorubicin | Doxil | ATI-0918|CAELYX|liposomal doxorubicin | Chemotherapy - Anthracycline 13 | Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06843447 | Phase Ib/II | Pembrolizumab + Raludotatug deruxtecan Bevacizumab + Paclitaxel + Raludotatug deruxtecan Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin Bevacizumab + Carboplatin + Gemcitabine Carboplatin + Raludotatug deruxtecan Bevacizumab + Carboplatin + Paclitaxel Paclitaxel + Raludotatug deruxtecan Bevacizumab + Raludotatug deruxtecan Bevacizumab + Carboplatin + Raludotatug deruxtecan | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Recruiting | USA | ISR | GBR | ESP | 0 |